Format

Send to

Choose Destination
Dig Dis Sci. 2016 Nov;61(11):3255-3260. Epub 2016 Sep 16.

Patients Perceive Clinical Benefit with the Specific Carbohydrate Diet for Inflammatory Bowel Disease.

Author information

1
Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sandpoint Way NE, Seattle, WA, 98105, USA. David.Suskind@seattlechildrens.org.
2
Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sandpoint Way NE, Seattle, WA, 98105, USA.
3
Children's Center for Digestive Health Care, Children's Healthcare of Atlanta, Atlanta, GA, USA.
4
Department of Medicine, Division of Gastroenterology, University of Washington Medical Center, Seattle, WA, USA.
5
Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA, USA.

Abstract

BACKGROUND:

Recent studies suggest that dietary therapy may be effective for patients with inflammatory bowel disease (IBD), but limited published data exist on the usage and efficacy of dietary therapy.

AIM:

To evaluate the perspective of IBD patients using the specific carbohydrate diet (SCD).

METHODS:

An anonymous online survey was conducted using REDCap, a Web-based survey tool. Survey links were sent to known Web sites as well as support groups in an attempt to characterize patient utilization of the SCD and perception of efficacy of the SCD.

RESULTS:

There were 417 respondents of the online survey on the SCD with IBD. Mean age for individuals on the SCD was 34.9 ± 16.4 years. Seventy percent were female. Forty-seven percent had Crohn's disease, 43 % had ulcerative colitis, and 10 % had indeterminate colitis. Individuals perceived clinical improvement on the SCD. Four percent reported clinical remission prior to the SCD, while 33 % reported remission at 2 months after initiation of the SCD, and 42 % at both 6 and 12 months. For those reporting clinical remission, 13 % reported time to achieve remission of less than 2 weeks, 17 % reported 2 weeks to a month, 36 % reported 1-3 months, and 34 % reported greater than 3 months. For individuals who reported reaching remission, 47 % of individuals reported associated improvement in abnormal laboratory values.

CONCLUSIONS:

The SCD is utilized by many patients as a primary and adjunct therapy for IBD. Most patients perceive clinical benefit to use of the SCD.

KEYWORDS:

Crohn’s disease; Diet; Inflammatory bowel disease; Nutrition; Specific carbohydrate diet; Ulcerative colitis

PMID:
27638834
DOI:
10.1007/s10620-016-4307-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center